Introduction: To assess the efficacy and safety of vildagliptin as add-on therapy in Japanese patients with type 2 diabetes mellitus (T2DM), inadequately controlled on stable long-acting, intermediate-acting, or pre-mixed insulin, with or without concomitant metformin.
n = 76; placebo, n = 75). Patient demographics and clinical characteristics were comparable between the groups at baseline. Addition of vildagliptin resulted in statistically significant reductions in HbA1c after 12 weeks (-1.01 ± 0.06%), with a between-treatment difference of -0.91 ± 0.09% (p\0.001). FPG levels reduced from baseline to 12 weeks in the vildagliptin group (-1.2 ± 0.2 mmol/L), with a between-treatment difference of -1.2 ± 0.3 mmol/L which was significant (p\0.001). The proportion of patients achieving HbA1c targets was higher with vildagliptin treatment for all pre-defined Electronic supplementary material The online version of this article (doi:10.1007/s13300-015-0147-6) contains supplementary material, which is available to authorized users.
INTRODUCTION
The increasing prevalence of type 2 diabetes mellitus (T2DM) poses a major health crisis globally. According to International Diabetes Federation estimates, 382 million people were affected with T2DM in 2013. This number is projected to increase up to 600 million by 2035, with Asia alone accounting for 60% of this population [1] .
In Japan, approximately 7 million people aged 20-79 years are affected with T2DM and the prevalence is dramatically increasing due to lifestyle changes, genetic predisposition, and the aging population [2, 3] . Mortality related to diabetes was 44% in patients aged \60 years in Japan, China, and other parts of the Western Pacific region [1] . The high prevalence of T2DM is associated with significant economic encumbrance, accounting for up to 6% of the total healthcare budget [3] .
Due to the progressive nature of T2DM, treatment intensification with oral antidiabetes drugs (OADs) is often required. However, despite the availability of several OADs and advancements in T2DM management, achieving glycated hemoglobin A1c (HbA1c) goal of \7% is still a challenge in most Asian countries including Japan [4] . Impaired insulin secretion and insulin resistance are two major pathophysiological features where insulin secretory response is severely impaired in T2DM patients, especially among Japanese population [5] .
In Japan, insulin is now being used more frequently, with *30% of patients receiving either a monotherapy or in combination with other OADs [6, 7] . Although pre-mixed insulin lowers fasting plasma glucose (FPG) and post-prandial glucose levels to some extent, it eventually fails to demonstrate adequate control over glycemic excursions [7] . Fear of increased risk of hypoglycemia and weight gain associated with insulin often results in delay in treatment initiation and intensification [8, 9] .
In addition, patients undergoing insulin treatment gradually develop a syndrome called Impaired Awareness of Hypoglycemia (IAH), in which the ability to identify the onset of hypoglycemia becomes progressively impaired and thus the complications associated with hypoglycemia increase [10, 11] .
Hence, there is a need for OADs as an add-on to insulin that can improve glycemic control without increasing the risk of hypoglycemia and weight gain. Dipeptidyl peptidase-4 (DPP-4) inhibitors such as vildagliptin are being increasingly used for the treatment of diabetes in Japanese patients [12] . Further, concomitant use of insulin and a DPP-4 inhibitor has recently been included in the treatment algorithm [6] . The efficacy and tolerability of vildagliptin in combination with insulin, with or without metformin, has been demonstrated in randomized clinical trials in global populations including Asians [13] [14] [15] . However, there is still a dearth of data on the efficacy and safety of vildagliptin as an add-on therapy to insulin in Japanese patients with T2DM.
This 12-week, randomized, placebo-controlled study aimed to assess the efficacy and safety of vildagliptin 50 mg twice daily (bid) add-on therapy in Japanese patients with T2DM, inadequately controlled on insulin, with or without concomitant metformin treatment.
METHODS

Study Design and Patient Population
This was a 12-week, randomized, double-blind, placebo-controlled study conducted in Japan. doses taken more frequently than bid, or a total insulin dose exceeding 1 unit/kg/day for the past 12 weeks were also excluded. The dose of insulin was to be maintained within 10% variation from baseline throughout the study unless dose adjustments were required for safety reasons. Patients were stratified based on the use of metformin and type of insulin.
Efficacy and Safety Assessments
The primary endpoint was the change in HbA1c from baseline to 12 weeks. Secondary efficacy endpoints included responder rates based on 
Statistical Analysis
Assuming a withdrawal rate of 5%, a sample size of 152 patients with T2DM treated with insulin were randomized to provide 90% power to 
Ethics and Good Clinical Practice
The study protocol was reviewed and approved by the Independent Ethics Committee/ 
Efficacy
The mean change in HbA1c over 12 weeks of treatment is represented in Fig. 3a . Vildagliptin demonstrated consistent reductions in mean HbA1c compared to placebo throughout the study. The adjusted mean change in HbA1c from baseline to study endpoint was -1.01 ± 0.06 and -0.11 ± 0.06% in the vildagliptin and placebo groups, respectively, with a between-treatment difference of -0.91 ± 0.09% (p\0.001) (Fig. 3b) . The proportion of patients achieving target HbA1c \7% were distinctly higher in the vildagliptin group compared to placebo for all pre-defined responder categories ( (Table 3) . Reductions in FPG were also consistent throughout the study (Fig. 4a ). The adjusted mean change in FPG from baseline to endpoint was -1.2 ± 0.2 vs. -0.02 ± 0.2 mmol/L in the vildagliptin and placebo groups, respectively, with a betweentreatment difference of -1.2 ± 0.3 mmol/L (p\0.001; Fig. 4b ).
Safety
Vildagliptin 50 mg bid added to long-acting, intermediate-acting or pre-mixed insulin, with or without metformin was generally safe and well tolerated. The overall incidence of AEs was similar and comparable between the vildagliptin (46.2%) and placebo (43.6%) groups ( (Table 5 ). Of the 9 events, 3 were triggered by strenuous exercise, 3 events by missed/delayed meals, and the remaining 3 events had no precipitating events specified.
However, there was no severe hypoglycemia or any event reported, leading to study drug discontinuation. The overall incidence of hypoglycemic events was low and all hypoglycemic events were self-treatable using non-drug therapy.
DISCUSSION
This randomized, placebo-controlled, parallel-group study is the first report to demonstrate the efficacy and safety of vildagliptin 50 mg bid as add-on therapy in Japanese patients inadequately controlled on insulin, with or without concomitant metformin. In this study, vildagliptin treatment was well tolerated with a safety profile similar to placebo group and the results were consistent with earlier studies [13] [14] [15] .
Vildagliptin 50 mg bid treatment demonstrated a clinically and statistically Differences between treatment with vildagliptin and placebo were statistically significant for all responder rate categories.
Vildagliptin was well tolerated with overall incidence rate of AEs similar to that of placebo (46.2%, vildagliptin vs. 43.6%, placebo). The incidence of hyperhidrosis, hunger, tremor, and hypoglycemia was more common in the vildagliptin group than in the placebo group.
The percentage of patients discontinued due to AEs was low and comparable between treatment groups. There were no patients with treatment-emergent hepatic enzyme elevation or deaths reported in the study. The overall incidence of hypoglycemic events was low in both the groups, but was higher in the vildagliptin-treated patients (6.4%, HbA1c *7%) compared with placebo-treated patients (1.3%, HbA1c *8%). None of the patients reported any severe hypoglycemia that required assistance of another person. Similar findings about a very low proportion of patients experiencing hypoglycemic events with vildagliptin treatment were reported in previous studies [13] [14] [15] . Efficacy and safety Baseline is the measurement obtained on day 1 or the sample obtained on an earlier visit (scheduled or unscheduled) which was closest to day 1, if day 1 measurement is missing. Study endpoint is defined as the final available post-randomization assessment obtained at any visit (scheduled or unscheduled), prior to the start of major changes in insulin background therapy, up to the final scheduled visit including week 12 bid twice daily, HbA1c glycated hemoglobin, SE standard error findings observed from this study are in line with data obtained from other gliptins including alogliptin, saxagliptin, and linagliptin as add-on to insulin in terms of effective HbA1c reduction and similar incidence rates of AEs [16] [17] [18] .
Insulin therapy is generally associated with increased risk of hypoglycemia, which often is a barrier in achieving good glycemic control.
Prolonged use of insulin is associated with IAH, which could also increase the risk of hypoglycemia and complications associated with it [10, 11] . Furthermore, intensive glucose control resulted in severe hypoglycemia requiring assistance in 0.4-1.5% as reported in ADVANCE (ClinicalTrials.gov Identifier, NCT00145925) and ACCORD trials (ClinicalTrials.gov Identifier, NCT00000620) [19, 20] . 
